Effect of the adenovirus-mediated monocyte chemoattrarctant protein-one (MCP-1) gene and NK4 gene co-expression in pancreatic cancer cell

doi:10.3877/cma.j.issn.1647-0793.2013.03.001

Abstract

Abstract:

Objective

To investigate the effect of the adenovirus-mediated NK4 and MCP-1 gene co-expression in pancreatic cancer cell in vitro.

Methods

NK4 gene and MCP-1 gene were singly and conjointly transfected into pancreatic cancer cells SW1990 by adenovirus vector. The expressions of NK4 and MCP-1 were detected using RT-PCR and ELISA. Then the influence on the growth of pancreatic cancer cells and vascular endothelial cells were observed.

Results

When MOI was 60 efu/cell, the infection efficiency of SW1990 was 100%. The expression of MCP-1 and NK4 mRNA were the highest in the 5th days in all the three groups. The expressions of MCP-1 and NK4 in conjoint group were lower than either single MCP-1 or single NK4 group. There was no significant difference in the growth curve of all the three and control groups. Both AD-NK4 and conjoint groups can inhibit the growth of vascular endothelial cells, but no significant difference was found between the two groups.

Conclusions

Adenovirus-mediated NK4 and MCP-1 genes can effectively infect SW1990, and did not show inhibiting effect in vitro. However, NK4 may play the role of tumor suppressor through inhibiting tumor angiogenesis.

Key words: Pancreatic neoplasms, Heptatocyte growth factor, Monocyte chemoattractant protein 1, Genetic therapy, Adenovirus

Hua-ping ZHOU, He-ping PENG, Qi-cai LIU. Effect of the adenovirus-mediated monocyte chemoattrarctant protein-one (MCP-1) gene and NK4 gene co-expression in pancreatic cancer cell[J]. Chinese Archives of General Surgery(Electronic Edition), 2013, 07(03): 165-169.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1647-0793.2013.03.001

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2013/V07/I03/165

Figures/Tables 3

References 11

1	Date K, Matsumoto K, Shimura H, et al. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett, 1997, 420(1): 1-6.
2	Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci, 2003, 94(4): 321-327.
3	Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol, 2004, 14(3): 149-154.
4	Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control, 2000, 7(5): 421-427.
5	王琳，郭永章，李立, 等. 单纯疱疹病毒Ⅱ型胸苷激酶基因对人原发性肝细胞癌治疗作用的实验研究. 中华肝胆外科杂志, 2003, 9(5): 306-308.
6	Drozdzik M, Qian C, Xie X, et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J Hepatol, 2000, 32(2): 279-286.
7	Otte JM, Kiehne K, Schmitz F, et al. C-Met protooncogene expression and its regulation by cytokines in the regenerating pancreas and in pancreatic cancer cells. Scand J Gastroenterol, 2000, 35(1): 90-95.
8	Kushibiki T, Matsumoto K, Nakamura T, et al. Suppression of the progress of disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized gelatin microspheres. Pharm Res, 21(7): 1109-1118.
9	Murakami M, Nagai E, Mizumoto K, et al. Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int J Cancer, 2005, 117(1): 160-165.
10	Saimura M, Nagai E, Mizumoto K, et al. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin Cancer Res, 2002, 8(10): 3243-3249.
11	Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res, 2003, 63(21): 7451-7461.

[1]	Yingying Ge, Jin Yue, Lingfa Xue, Yaoxiang Xu, Haoran Zhao, Mingxue Cui, Wenlin Xiao. Effect of targeting p38MAPK on scar hyperplasia after rabbit cleft lip repair in vivo [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(01): 37-44.
[2]	Siya Shi, Shiting Feng, Bingqi Shen. Progress in the non-invasive evaluation of interstitial fibrosis and targeted therapy for pancreatic ductal adenocarcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(06): 443-447.
[3]	Juan Ning, Xiaoyan Wang, Huaping Wei. Efficacy of albumin bound paclitaxel in the treatment of metastatic pancreatic cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(06): 407-411.
[4]	Chengpeng Jia, Daihong Wang, Hua Chen, Bei Sun. Establishment and application of preoperative prognostic model for resectable pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 566-570.
[5]	Xianlin Han. Total laparoscopic radical pancreaticoduodenectomy after neoadjuvant chemotherapy（combined with superior mesenteric vein resection and artificial vascular reconstruction） [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 133-133.
[6]	Weilin Guo, Yuntao Li, Peizhong Shang, Xiaowu Li, Wei Li. Expression of S100A4 and Midkine in pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 149-152.
[7]	Yuan Zhang, Xiaolong Li, Yapeng Wang. Relationship between ANGPTL2 protein and immunosuppressive cell infiltration in pancreatic cancer and its clinical significance [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 145-148.
[8]	Yongning Li, Xueqin Fu, Ying Li, Peng Liu, Songbai Liu, Yaozhen Pan. Gene similar sequence family member 126A targets vimentin to promote invasion and migration of pancreatic cancer cells and its mechanism [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 139-144.
[9]	Yonghuan Mao, Ling Xi, Chen Lu, Lixiang Liu, Chunzhao Yu, Xiaofei Shen. PI3K/Akt signaling pathway influences the chemotherapy sensitivity of PANC-1 to gemcitabine in pancreatic cancer cells via Plk1 [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 135-138.
[10]	Xianlin Han, Bozheng Lin, Xiafei Hong. Research advances in laparoscopic surgery for pancreatic cancer and key points of vascular dissection [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 129-132.
[11]	Feng Tian, Junchao Guo. Current status and prospect of minimally invasive surgery in pancreatic cancer in China [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 124-128.
[12]	Taiping Zhang, Guihu Weng, Yueze Liu. Promoting the standardization of laparoscopic surgery for pancreatic cancer in China continuously [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 120-123.
[13]	Bo Zhang, Wei Han, Shaolong Hao, Zeqian Li, Zhili Ji. Advances in competing endogenous Rnas in pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 213-216.
[14]	Zeqian Li, Shaolong Hao, Bo Zhang, Kailun Ji, Wei Han. Research progress of peripheral blood non-coding RNA in pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 217-220.
[15]	Di Wang, Shaocheng Lyu, Jincan Huang. Pancreatic metastasis of lung adenocarcinoma with portal vein invasion: a case report [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 457-460.

Please choose a citation manager

Content to export